Side effects of CT-guided implantation of $^{125}$I seeds for recurrent malignant tumors of the head and neck assisted by 3D printing non co-planar template

Yuliang Jiang¹, Zhe Ji¹, Fuxin Guo¹, Ran Peng¹, Haitao Sun¹, Jinghong Fan¹, Shuhua Wei¹, Weiyan Li¹, Kai Liu², Jinghua Lei³ and Junjie Wang¹*

Abstract

Background: For the recurrence of head and neck cancer after operation and radiotherapy, the local control of radioactive seed implantation is good, and it has a certain palliative effect. This study aims to investigate the acute and late side effects of a three-dimensional printing non co-planar template (3D–PNCT) for computed tomography (CT)-guided radioactive $^{125}$I seed (RIS) implantation in recurrent cancer of the head and neck.

Methods: Between January 2016 and December 2016, forty-two patients with local recurrent malignant tumors of the head and neck received 3D–PNCT-assisted RIS implantation. The prescribed dose was 110–160 Gy. Preoperative planning design, production of individual guide plates, RIS implantation, postoperative dose evaluation, and follow-up were completed for all patients. Side effects in the skin, mucous membranes, blood and spinal cord were evaluated.

Results: All patients underwent surgery successfully. Duration of follow-up was 4–14 (median, of 8.5) months. The activity of a single RIS was 0.34–0.7 (median, 0.6) mCi. The number of RIS was 10–126 (median, 34). The number of implantation needles was 4–31 (median, 11). The mean D2cc (dose to the most exposed 2-cc volume) and D0.1cc (dose to the most exposed 0.1-cc volume) of the skin were 24.9 (7.1–85.5) and 47.5 (9.4–167.2), respectively, whereas those of the spinal cord were 8.4 (4.5–33.3) and 14.2 (13.6–63.0), mucosa were 35.1 (4.2–82.8) and 87.0 (6.6–214.1), parotid glands were 16.2 (12.8–19.7) and 29.8 (26.1–33.4) and those of the trachea were 17.9 (2.5–45.9) and 32.7 (3.9–83.9), respectively. No case had an acute reaction of grade ≥3. Three cases had a grade-1 skin reaction. Blood toxicity did not occur, nor spinal-cord injury. Xerostomia was not aggravated than that of before brachytherapy. One case had a grade-3 nerve response.

Conclusions: 3D–PNCT-assisted RIS implantation can provide good accuracy for positioning. For local recurrent malignant tumor of head and neck, there were no obvious adverse reactions.

Keywords: 3D printing non co-planar template, $^{125}$I seed implantation, Side effect, Head and neck carcinoma

* Correspondence: junjiewang_edu@sina.cn
¹Department of Radiation Oncology, Peking University Third Hospital, 49 Huayuan North Road, Beijing 100191, People’s Republic of China

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Implantation of radioactive $^{125}$I seeds (RIS) is a minimally invasive, safe and effective treatment for malignant tumors. As a radical method for the treatment of early-stage prostate cancer, its long-term efficacy is comparable with that of surgery or external beam radiotherapy (EBRT), but the extent of trauma and number of adverse reactions are much less [1, 2]. RIS implantation also plays an important role in the treatment of tumors of the head, neck, lungs, pancreas, and rectum [3–6]. In terms of recurrent tumors of the head and neck, most patients have already undergone surgery and/or EBRT and chemotherapy for the primary tumor, so treatment is a challenge. For this group of patients, RIS implantation can be good palliative salvage treatment [3, 7, 8].

In recent years, some scholars have taken advantage of computer-aided design and rapid prototyping to design three-dimensional printing non co-planar template (3D–PNCT) to assist and improve the accuracy of RIS implantation into tumors [9–12]. However, few studies have focused on the side effects of RIS implantation, and there are no reports on the side effects of using a 3D–PNCT. We investigated the side effects of use of a 3D–PNCT combined with computed tomography (CT)-guided RIS implantation for treatment of malignant tumors of the head and neck.

Methods
General information
Forty-two patients with recurrent/metastasis of a malignant tumor of the head and neck who received RIS implantation assisted by a 3D–PNCT and CT guidance in our hospital from January 2016 to October 2016 were enrolled. Among them, 26 cases had recurrence of a primary tumor of the head and neck and 16 cases had a metastatic tumor of the neck. Also, 64.3% (27/42) of the patients had undergone head and neck surgery, 85.7% (36/42) of cases had accepted EBRT, and 69% (29/42) of cases had a history of chemotherapy. The Karnovsky Performance Status (KPS) score of all patients was > 70. General information of the patients is shown in Table 1. According to the literature and clinical experiences within our center, 110–160 Gy was the recommended for prescription doses [3, 5, 7, 8, 13–19].

Preoperative planning design
All patients underwent spiral CT (Brilliance Big Bore; Philips, Amsterdam, the Netherlands) 2 days before surgery. Patients were positioned prone or supine position according to the tumor site. Then, patients were fixed with vacuum pads and marked with a positioning line on the body surface. CT data were transmitted to a Brachytherapy Treatment Planning System (B-TPS). A RIS implantation planning system was designed by the
Imaging Center of the Beijing University of Aeronautics and Astronautics and Astronautics (Beijing, China) for preoperative planning. The designed treatment plan on 2D and 3D CT images involved: (i) delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs); (ii) setting of the prescribed dose and RIS activity; (iii) determination of the needle tract of the implanted RIS (insertion direction, distribution, and depth); (iv) calculation of the RIS number and simulation of the spatial distribution of RIS; (v) calculation of the dose distribution of the target volume and OARs (parotid gland, spinal cord, trachea, mucous membrane, skin, important blood vessels in the neck). We optimized the plan to make the doses of 90% GTV (D90 of GTV) reach the prescribed doses (110–150 Gy) as far as possible while ensuring that the exposure dose to OARs was as low as possible.

**Design and production of individual templates**

Depending on B-TPS data, we used 3D images and reverse-engineering software to establish a digital model for the individual template. Coordinates for the spatial points of RIS and needle-tract orientation were incorporated into the model. Then, we used 3D rapid-prototyping equipment with photo-curable resins to print individualized 3D templates. The template contained the superficial anatomic characteristics of the treatment area, positioning markers and simulation of the needle tract.

**Puncture and implantation of $^{125}$I seeds**

Local anesthesia was induced in all patients. The 3D–PNCT was placed on the surface of the treatment area of the patient. The 3D–PNCT was aligned accurately with the outer-contour features, positioning marks, and positioning laser line. Through the guide hole of the 3D–PNCT, we inserted 3 stable needles (Mick Radio Nuclear Instruments, Mount Vernon, NY, USA) percutaneously to pre-planned depths. We carried out CT immediately to validate the locations of stable needles and, if necessary, fine-tuned the intraoperative plan in real time. Finally, depending on preoperative and intraoperative planning, we implanted the RIS in a retrusive manner with a Mick gun (Mick Radio Nuclear Instruments of the USA). Iodine-125 seeds (Tian Jin Sai De Tech Co., Ltd. Atom High Tech Co., Ltd. Chinese Tong Fu Tech Co., Ltd.) with half life of 59.4 days and dose rate constant of 0.965 cGy/(h·U). CT was undertaken immediately after completion of RIS implantation to observe the actual distribution of RIS (Fig. 1).

**Postoperative verification of dosimetry and evaluation of plans**

Dosimetric evaluations of GTV and adjacent OARs were based on postoperative CT images.

**Follow-up and research focus**

Tumor response was evaluated at 4 weeks and every 2–3 months thereafter. Follow-up involved regular visits and telephone conversations.

The side effects of skin puncture were bleeding, pain, infection, non-union of puncture point, and metastasis due to RIS implantation. The side effects of radiation (which were scored using the toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) were skin injury, mucosal response, spinal-cord injury, peripheral-nerve injury, xerostomia and blood toxicity [20]. Nerve injury was scored by the Common Terminology Criteria for Adverse Events v4.0 [21]. Acute toxicities were evaluated in the first 2 months, and late toxicity were evaluated in 2 months later.

The seed migration, one of specific complications of RIS implantation, was observed during the follow-up period.

**Statistical analyses**

With regard to side effects, the chi-squared test was used to analyze significant differences among the grades for the same factor. Related factors were the dose absorbed by the OARs, previous accumulative dose, and preoperative physical condition of the OARs.

**Results**

**Treatment and related complications**

All forty-two patients completed CT-guided RIS implantation assisted by a 3D–PNCT. The activity of a single RIS was 0.34–0.7 (median, 0.6) mCi. The number of RIS was 10–126 (median, 34). The number of implantation needles was 4–31 (median, 11). All but one episodes of intraoperative pain were tolerable well and disappeared after the surgical procedure. One case had severe intraoperative pain that was barely tolerable, but was relieved postoperatively. Intraoperative bleeding was not obvious. No patients suffered infection at the puncture site after RIS implantation. Skin healing at the puncture site was good except for two cases in which the healing time was delayed for 1 week due to exudation. Metastasis due to RIS implantation was not found during follow-up.

**Side reactions of radiation**

All the patients were followed up, and the follow-up rate was 100%. The follow-up time was 4 ~ 14 months (median, 8.5 months).

No case had an acute reaction of grade $\geq 3$. Three cases had a grade-1 skin reaction: one case had a grade-1 mucosal reaction and two cases a grade-2 reaction. Blood toxicity was not observed.

...
With regard to late responses, spinal-cord injury did not occur. Xerostomia was not aggravated. One case had a grade-3 nerve response. Preoperatively, this patient had an abnormal sensation with tumor invasion of the brachial plexus and weak lifting force (strength was level 4). Three months after brachytherapy, the tumor had nearly disappeared, but the neurologic symptoms were aggravated, the abnormal sensation was more obvious than before, and the lifting force was weaker (level 3). The nerve reaction worsened from level 2 (preoperative) to 3 (postoperative) (Common Terminology Criteria Adverse Events v4.0). Thus, we speculated that it was more likely to be a radiation-induced nerve injury. However, no evidence could exclude the possibility of tumor invasion because irreversible nerve injury had occurred preoperatively which worsened postoperatively. The severity of the skin reaction was related to the absorbed dose (D0.1cc) ($P = 0.011$). There was little evidence that skin edema and fibrosis were related to the accumulative dose of previous EBRT. One case had nerve injury which might have been related to tumor involvement on nerves. RIS translocation did not occur (Tables 2, 3 and 4).

**Discussion**

Treatment of recurrent cancer of the head and neck includes reoperation, repeat radiotherapy, and systemic

---

**Fig. 1** The CT tomographic images of the preimplant and postimplant plan. (Squamous carcinoma of the esophagus yT2N1M1b. Stage IV. Right clavicular lymph node metastasis, EBRT:DT60Gy before). The first column lists all the CT tomographic images of the preimplant plan. The second column shows locations of needles before implantation the RIS. The third column lists the images of the postimplant plan in which includes seeds positions, dosimetric evaluations of GTV and adjacent OARs.
chemotherapy. Because of the previous surgery and/or radiotherapy, the difficulty of reoperation and EBRT increases. In addition, the important anatomic structures of the head and neck, as well as the requirements of functional preservation and cosmetic effect, restrict reoperation and EBRT. However, studies have shown that RIS implantation in the treatment of recurrent cancer of the head and neck has a good palliative effect, good local control, and mild side effects [3, 7, 8].

In recent years, with the development of 3D printing technology, 3D–PNCT-assisted RIS implantation has improved the accuracy of carrying out treatment planning [11, 22–24]. With regard to postoperative verification, the parameters of the conformity index, external index and tumor prescribed doses have coincided closely with that of preoperative planning. Furthermore, application of 3D–PNCT-assisted RIS implantation can be used to predict the doses absorbed by tumors and normal tissues.

Because of the physical characteristics of RIS, the dose absorbed by peripheral tissues declines rapidly, so the side effects are slight. In our previous study on non-template-guided RIS implantation in the treatment of recurrent/metastatic tumors of the head and neck, no side effect was beyond grade 3 [7, 8] and the prevalence of grade-1 and -2 side effects was 21% [8]. With regard to RIS implantation for treatment of metastatic lymph

---

**Table 2** Absorbed doses of organs at risks in 3D–PNCT-assisted $^{125}$I seed implantation salvage treatment for recurrent malignant tumors of the head and neck

|                | D2cc Mean (Gy) | D2cc Interval (Gy) (standard deviation) | D0.1cc Mean (Gy) | D0.1cc Interval (Gy) (standard deviation) |
|----------------|----------------|----------------------------------------|------------------|-------------------------------------------|
| Skin           | 24.9           | 7.1–85.5 (23.1)                        | 47.5             | 9.4–167.2 (51.2)                          |
| Spinal cord    | 8.4            | 4.5–33.3 (9.5)                         | 14.2             | 13.6–63.0 (17.1)                         |
| Mucosa$^a$     | 35.1           | 4.2–82.8 (31.1)                        | 87.0             | 6.6–214.1 (84.0)                         |
| Parotid glands$^a$ | 16.2       | 12.8–19.7 (49.1)                      | 29.8             | 26.1–33.4 (51.3)                        |
| Trachea$^a$    | 17.9           | 2.5–45.9 (14.8)                        | 32.7             | 3.9–83.9 (28.6)                         |

$^a$The dose absorbed by this organ was evaluated in some cases. If the tumor margin was < 5 cm and the CT did not include this organ, we did not estimate its dose.

---

**Table 3** Prevalence of side effects in 3D–PNCT-assisted $^{125}$I seed implantation salvage treatment for recurrent malignant tumors of the head and neck

|                        | Cases | Percentage |
|------------------------|-------|------------|
| Puncture-related adverse reaction |       |            |
| Bleeding               | 0     |            |
| Increased pain         | 1     | 2.4%       |
| Infection              | 0     |            |
| Skin non-union         | 0     |            |
| Implantation metastasis| 0     |            |
| Radiation-related adverse reaction |       |            |
| Early skin reaction    |       |            |
| I                      | 3     | 7.2%       |
| II                     | 0     |            |
| III                    | 0     |            |
| IV                     | 0     |            |
| Late skin reaction     | 0     |            |
| Early mucosal reaction |       |            |
| I                      | 1     | 2.4%       |
| II                     | 2     | 4.8%       |
| III                    | 0     |            |
| IV                     | 0     |            |
| Late skin reaction     | 0     |            |
| Increased xerostomia   | 0     |            |
| Blood toxicity         | 0     |            |
| Increased myelitis     | 0     |            |
| Radiation-based nerve injury |       |            |
| 1$^a$                  | 1     | 2.4%       |

$^a$Tumor invasion of the brachial plexus and weak lifting force (strength level = IV). Three months after surgery, the tumor nearly disappeared, but the neurologic symptoms were aggravated, the abnormal sensation was more obvious than before, and the force was weaker (level III). The nerve reaction worsened from level II (preoperative) to level III (postoperative) (CTC v4.0). Thus, we speculated that it was more likely to be a radiation-based nerve injury.

---

**Table 4** The chi-squared test of skin and mucosal reactions

|                        | Chi square | $P$  |
|------------------------|------------|------|
| Skin reaction          |            |      |
| D2cc (< 30 vs. ≥30 Gy) | 4.1        | 0.091|
| D0.1cc (< 60 vs. ≥60 Gy)| 10.1       | 0.011|
| Previous accumulative dose (< 60 vs. ≥60 Gy)| 0.94 | 0.54 |
| Mucosal reaction       |            |      |
| D2cc (< 30 vs. ≥30 Gy) | 0.68       | 0.41 |
| D0.1cc (< 60 vs. ≥60 Gy)| 3.8        | 0.2  |
| Previous accumulative dose (< 60 vs. ≥60 Gy)| 0.94 | 0.54 |

D2cc: the dose to 2 cc volume, D0.1cc: the dose to 0.2 cc volume
nodes, the prevalence of grade-1 and -1 side effects was 2.8%, and that for grade ≥ 3 was 2.8% [12]. Jinghua et al. [25] undertook surgery with simultaneous RIS implantation. The peripheral matching dose was 60 Gy, patients were not treated with external EBRT, and the prevalence of adverse reactions was 3.6%. Jianguo et al. [26] treated recurrent tumors of the head and neck with RIS implantation, and the prevalence of grade-1 and -2 side reactions (mainly those of skin and mucous membranes) was 24.3%; no case had a side reaction beyond grade-3. Jianguo et al. [27] after adjuvant RIS implantation for patients with oral and maxillofacial tumors with a prescribed dose of 60 Gy, found that 2% of cases had a grade-3 skin reaction and 5.2% of cases had a grade-1 or –2 skin reaction. Taken together, these reports demonstrated that the side effects of RIS implantation were, in general, low.

In the present study, during follow-up, only one case had a worse nerve reaction that developed from grade 2 preoperatively to grade 3 postoperatively. We speculated that it might have been a treatment-associated side reaction. Reactions in the skin and mucous membrane were all below grade 2, and their prevalence was low (7.2%). Compared with the literature, side effects were improved slightly or to a same extent [3, 7, 8]. According to a preliminary statistical analysis, in three cases with a grade-1 skin reaction, the effect was related to the dose absorbed by the OARs (D0.1cc), whereas the skin reaction was not related significantly to D2cc or the previous accumulative dose of EBRT. The prevalence of side effects was low, besides, there was no significantly difference among the different groups of the correlative factors. In future studies, larger study cohorts will be required.

**Conclusions**

Our data show that 3D–PNCT-assisted RIS implantation for the treatment of cancer of the head and neck could guarantee the accuracy of the procedure and provide a reliable absorbed dose of the target volume and OARs. Preliminary results showed no observable side effects. We plan to use larger patient cohorts and clarify its efficacy and safety.

**Abbreviations**

125I: Iodine-125; 3D–PNCT: Three-dimensional printing non-coplanar template; CT: Computer tomography; GTV: the Gross target volume; KPS: Karnofsky performance status; OARs: Organ at risks; RIS: Radioactive 125I seed

**Acknowledgments**

We would like to thank the native English speaking scientists of Eliogen Company (Huntington Beach, California) for editing our manuscript.

**Funding**

This work was supported by the Capital Characteristic Clinic Project [grant number Z151100004015171].

**Availability of data and materials**

The authors declare that all data supporting the findings of this study are available within the article.

**Authors’ contributions**

YJ, KL, J were responsible for collection of clinical data. YJ collected the data and drafted the manuscript. JW was in charge of verifying patients’ implantsation plans and directing the writing. ZJ, FG, RP, JF, SW and WL are responsible for the supplement and refinement of clinical data and collectively carried out the implantation plan. HS was responsible for the design and production of radioactive seeds implantation plan and 3D-printing templates. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study protocol was approved by the Ethics Committee of Peking University Third Hospital [IRB00006761]. All patients provided written informed consent to participate in this study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Radiation Oncology, Peking University Third Hospital, 49 Huayuan North Road, Beijing 100191, People’s Republic of China.

2. Department of Oncology, Dingzhou City People’s Hospital, Dingzhou 073000, China.

3. Department of Oncology, Shiyian City People’s Hospital, Shiyian 442000, China.

**Received:** 1 June 2017 Accepted: 16 January 2018

**Published online:** 03 February 2018

**References**

1. Mohan R, Schellhammer PF. Treatment options for localized prostate cancer. Am Fam Physician. 2011;84(4):413.

2. Wang JJ, Huang Y, Ran WQ, et al. Transperineal ultrasound guided (~125I) seed implantation combined with endocurietherapy for stage T1-T2 prostate cancer. J Modern Oncol. 2009;17(1):1217–2178.

3. Meng N, Jiang YL, Wang JJ. Permanent implantation of iodine-125 seeds as a salvage therapy for recurrent head and neck carcinoma after radiotherapy. Cancer Invest. 2011;29(3):236–42. https://doi.org/10.1080/07328400903453986.

4. Wang ZM, Lu J, Liu T. CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer. Lung Cancer. 2011;74(2):253–7. https://doi.org/10.1016/j.lungcan.2011.03.006.

5. Wang H, Wang J, Jiang Y. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2013;32:106. https://doi.org/10.1186/1756-9966-32-106.

6. Wang JI, Yuan HS, Li JN. Interstitial permanent implantation of 125 I seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Color Dis. 2009;24(4):391–9. https://doi.org/10.1007/s00384-008-0628-4.

7. Jiang YL, Meng N, Wang JJ. Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck. Cancer Biol Ther. 2010;9(12):959–66. https://doi.org/10.4161/cbt.9.12.11700.

8. Yu LJ, Na M, Wang JJ, et al. CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers. Radiat Oncol. 2010;5(1):58.

9. Liu SM, Zhang JG, Huang MW. Feasibility of permanent interstitial brachytherapy for skull base region through individual template assistance. Chin J Radiol Med Prot. 2013;33(1). https://doi.org/10.13760/cjrpm.0254-5098.2013.01.011.

10. Zhao YJ, Wang Y, Huang MW. Digital design method of individual guide plate for brachytherapy. Chin J Stomatol. 2014;49(2):13–8. https://doi.org/10.13760/cjss.0100098.2014.02011.

11. Yu LJ, Hao W, Zhe J. Computed tomography image-guided and personalized 3D printed template-assisted 125-iodine seed implantation for recurrent pelvic tumor: a dosimetric study. Chin J Radiat Oncol. 2016;25(9):959–64.
12. Yu LJ, Yue M, Jun JW. Implantation of 125I seeds for recurrence cervical node of head and neck tumor after external beam radiotherapy. Chin J Radiat Oncol. 2011;20(2):91–4.
13. Zhu L, Jiang Y, Wang J. An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy. World J Surg Oncol. 2013;11:60. https://doi.org/10.1186/1477-7819-11-60.
14. Cao Q, Wang H, Meng N. CT-guidance interstitial (125)iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors. Radiat Oncol. 2014;9(1):301. https://doi.org/10.1186/s13014-014-0301-8.
15. Meng N, Zhang X, Liao A. Management of recurrent alveolar soft-part sarcoma of the tongue after external beam radiotherapy with iodine-125 seed brachytherapy. Head Neck. 2014;36(12):125–8. https://doi.org/10.1002/hed.23648.
16. Qu A, Wang H, Li J. Biological effects of (125)I seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Investig. 2014;32(6):209–17. https://doi.org/10.3109/07357907.2014.905585.
17. Yang R, Wang J, Zhang X. Implementation of incident learning in the safety and quality management of radiotherapy: the primary experience in a new established program with advanced technology. Biomed Res Int. 2014;2014:392596. https://doi.org/10.1155/2014/392596.
18. Jiang P, Liu C, Wang J, et al. Computed tomography (CT)-guided interstitial permanent implantation of (125)I seeds for refractory chest wall metastasis or recurrence. Technol Cancer Res Treat. 2015;14(1):11–8.
19. Lin L, Wang J, Jiang Y. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma. Technol Cancer Res Treat. 2015;14(2):201–7. https://doi.org/10.7785/tcrt.2012.500409.
20. Cox JD, Stett J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.
21. Gay HA, Dyk P, Deasy JO, et al. Common terminology criteria for adverse events (CTCAE) v4.0 based hybrid patient and physician questionnaire for head and neck (HN) radiotherapy symptom reporting. Int J Radiat Oncol Biol Phys. 2011;81(2):S673.
22. Yu LJ, Bin L, Zhe J. Analysis of position errors of 3D printing individual non-coplanar template for radioactive seed implantation for malignant tumor. Chin J Radiol Med Prot. 2016;36(12):913–6.
23. Huang MW, Liu SM, Zheng L. A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck. J Radiat Res. 2012;53(6):973–7. https://doi.org/10.1093/jrr/rsr046.
24. Zhe J, Yu LJ, Fu XG. Dosimetry verification of radioactive seed implantation for malignant tumor assisted by 3D printing individual guide template. Chin J Radiol Med Prot. 2016;36(9):662–6.
25. Jing HC, Yong MQ, Ning G. Clinical observation of operation combined with I-125 seed brachytherapy on oral and maxillofacial malignancy. J Med Forum. 2012;33(5):127–8.
26. Jian GZ, Jie Z, Tie LS. Radioactive seed implantation in treatment of oral and maxillofacial malignancy. Chin J Stomatol. 2006;41(8):464–6. https://doi.org/10.3969/j.issn.1002-0098.2006.08.005.